Clinical trials: Resistant Arterial Hypertension
Resistant Hypertension
Renal Sympathetic Denervation by Iberis System in Patients With Uncontrolled Hypertension - Iberis-HTN Registry
The purpose of this study is to document safety and efficacy of renal sympathetic denervation treatment in subjects with uncontrolled hypertension by using Iberis renal denervation system.
- Trial name
- Iberis (NCT02295683)
- Testing
- Renal Denervation
- Where
- 2 sites in Serbia, Spain
- Volunteers
- 18 people
- Sponsor
- Terumo Europe N.V.
High Blood Pressure
Verification of the Efficacy and Safety of the BAROSTIM NEO System in the Treatment of Drug Resistant Hypertension
To assess the long-term safety and efficacy of the BAROSTIM NEO System in trial (NCT01471834) participants.
- Trial name
- NCT01471834
- Testing
- BAROSTIM NEO System, Medical Management
- Where
- 9 sites in Canada, Germany and 1 more
- Volunteers
- 40 people
- Sponsor
- CVRx, Inc.
METABOLIC SYNDROME, HYPERTENSION
A 16 Week Study to Evaluate the Effect on Insulin Sensitivity of Valsartan (320 mg) and Hydrochlorothiazide (25 mg) Combined and Alone, in Patients With Metabolic Syndrome
The metabolic syndrome is a classification for patients with a constellation of risk factors which may include abdominal obesity, hypertension, elevated blood lipids and sugar.
- Conditions
- METABOLIC SYNDROME, HYPERTENSION, PRE-HYPERTENSION
- Trial name
- NCT00170937
- Testing
- valsartan plus hydrochlorothiazide
- Where
- United States
- Volunteers
- 507 people, healthy volunteers welcome
- Sponsor
- Novartis
Hypertension, Insulin Resistance
A Comparison of the Effect of Olmesartan Medoxomil, Losartan Potassium, and Atenolol on the Ability of Overweight Patients With High Blood Pressure to Respond to Insulin
To examine the effect of three different blood pressure medications on the insulin sensitivity in overweight patients with high blood pressure.
- Conditions
- Hypertension, Insulin Resistance, Metabolic Syndrome
- Trial name
- NCT00185094
- Testing
- Olmesartan medoxomil, Losartan potassium, Atenolol
- Where
- 10 sites in United States
- Volunteers
- 60 people
- Sponsor
- Daiichi Sankyo
Metabolic Syndrome, Diabetes
Evaluation of a Novel Self-Sampling Earwax Tool for Chronic Disease Biomarkers [TREARS STUDIES II]
Trears Biomarkers: A New Way to Manage Chronic Diseases Trears Biomarkers are changing how we care for chronic diseases by focusing on patients' needs.
- Conditions
- Metabolic Syndrome, Diabetes, Hypertension, Obesity and Obesity-related Medical Conditions
- Trial name
- Trears-II (NCT06932601)
- Volunteers
- 258 people
- Sponsor
- Trears
Pulmonary Arterial Hypertension
A Study of Single Doses of Frespaciguat (MK-5475) on Pulmonary Vascular Resistance (MK-5475-002)
This study of frespaciguat in participants with Group 1 pulmonary arterial hypertension (PAH) will assess the safety, tolerability and pharmacokinetics (PK) of inhaled frespaciguat. There is no formal hypothesis to be tested.
- Trial name
- NCT03744637
- Testing
- Frespaciguat
- Where
- Moldova
- Volunteers
- 25 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypertension
Telmisartan/Amlodipine (80/10) vs. Telmisartan/Amlodipine (40/10) vs. amlodipine10 in Resistant Hypertension
The primary objective of this trial is to demonstrate that the fixed dose combination of telmisartan 40mg + amlodipine 10mg (T40/A10) or the fixed dose combination of telmisartan 80mg + amlodipine 10mg (T80/A10) is superior in…
- Trial name
- NCT00553267
- Testing
- fixed dose combination of telmisartan+amlodipine, amlodipine
- Where
- 97 sites in Australia, Austria and 12 more
- Volunteers
- 947 people
- Sponsor
- Boehringer Ingelheim
Metabolic Syndrome
Metabolic Syndrome Observation on a Regional Basis
The aim of the study is to assess the prevalence of Metabolic Syndrome in Italy on a regional basis, defined according to NCEP/ATPIII Guidelines criteria.
- Trial name
- ORSA Umbria (NCT00933010)
- Where
- 3 sites in Italy
- Volunteers
- 1,600 people
- Sponsor
- AstraZeneca
Hypertension, Metabolic Syndrome X
Clinical EvaluatioN of TElmisartan-based Antihypertensive Regimen
To determine the efficacy and safety of telmisartan-based treatment among patients with metabolic syndrome in actual setting in Philippines.
- Trial name
- NCT00613314
- Where
- 122 sites in Philippines
- Volunteers
- 15,268 people
- Sponsor
- Boehringer Ingelheim
Hypertension
BAROSTIM THERAPY™ In Resistant Hypertension
The purpose of this registry (NCT02880631) is to evaluate the effect of BAROSTIM THERAPY with the BAROSTIM NEO System in the commercial setting in subjects recently implanted under the CE-Marked indication for resistant…
- Trial name
- NCT02880631
- Testing
- BAROSTIM NEO™ System
- Where
- 26 sites in Germany, Netherlands
- Volunteers
- 500 people
- Sponsor
- CVRx, Inc.
Multivessel Coronary Artery Disease, Hypertension Resistant to Conventional Therapy
Expand Management of Blood Pressure With Renal Denervation in Patients Undergoing Staged PCI for Advanced Coronary Artery diseasE
EMBRACE is a randomized, controlled, multicenter clinical study evaluating the effect of renal denervation on clinical adverse events in hypertensive patients undergoing staged percutaneous coronary intervention (PCI) for…
- Trial name
- EMBRACE (NCT07602790)
- Testing
- Renal denervation
- Volunteers
- 1,000 people
- Sponsor
- Ceric Sàrl
Resistant Hypertension
TrAnsCatHeter Intravascular Ultrasound Energy deliVery for rEnal Denervation (ACHIEVE)
The ACHIEVE study is a single-arm, open-label, prospective, post-market follow-up study to include up to one hundred (100) eligible patients as defined within the clinical investigational plan, with a twelve month follow-up…
- Trial name
- ACHIEVE (NCT01789918)
- Testing
- PARADISE percutaneous renal denervation
- Where
- 8 sites in Germany, Netherlands and 1 more
- Volunteers
- 96 people
- Sponsor
- ReCor Medical, Inc.
Hypertension
Endovascular Carotid Body Ablation in Patients With Treatment- Resistant Hypertension: A Safety and Feasibility Study
This is a prospective, observational, multicenter trial to evaluate the safety and feasibility of selective endovascular unilateral carotid body ablation in patients with treatment-resistant hypertension.
- Trial name
- NCT02099851
- Testing
- Carotid body ablation (Cibiem)
- Where
- 2 sites in Czechia, Poland
- Volunteers
- 6 people
- Sponsor
- Noblewell
Hypertension
A Multicenter Study to Evaluate the ROX Anastomotic Coupler System (ACS) In Patients With Severe Hypertension
The purpose of this study is to evaluate the safety and performance of the ROX Anastomotic Coupler System (ACS) in patients with severe hypertension.
- Trial name
- NCT01682057
- Testing
- ROX ANASTOMOTIC COUPLER SYSTEM (ACS)
- Where
- Belgium
- Volunteers
- 8 people
- Sponsor
- ROX Medical, Inc.
Resistant Hypertension, Uncontrolled Hypertension
Rapid Renal Sympathetic Denervation for Resistant Hypertension II
This is a global, multi-center, prospective, randomized, controlled study of the safety and effectiveness of renal denervation with the OneShot Renal Denervation System in patients with uncontrolled hypertension.
- Conditions
- Resistant Hypertension, Uncontrolled Hypertension, Renal Artery Ablation
- Trial name
- RAPID II (NCT01939392)
- Testing
- Renal Denervation (OneShot™ Renal Denervation System)
- Where
- Italy
- Sponsor
- Medtronic Endovascular
Resistant Hypertension
Symplicity China Study
The Symplicity China study will evaluate the real-world long-term safety, efficacy, and durability of the Symplicity Spyral system in a population of approximately 500 renal denervation treated subjects with up to 36 months of…
- Trial name
- NCT07081243
- Testing
- Symplicity Spyral Renal Denervation System
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Medtronic Vascular
Hypertension, Uncontrolled Hypertension
SMART Study in Real World
This study is a multicenter, single-arm, open-label and post-market study in a real world patient population with uncontrolled hypertension to document the long-term safety and efficacy of a renal mapping/selective renal…
- Conditions
- Hypertension, Uncontrolled Hypertension, Resistant Hypertension, Reduce Antihypertensive Drug Burden
- Trial name
- SMART-RW (NCT06780696)
- Testing
- SyMapCath I™ catheter and SYMPIONEER S1™ Stimulator/Generator
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- SyMap Medical (Suzhou), Ltd.
Pulmonary Arterial Hypertension
Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Participants
The purpose of this study was to investigate the effects of QTI571 (imatinib) on pharmacokinetics of bosentan and sildenafil at steady state when co-administered to participants with pulmonary arterial hypertension.
- Trial name
- NCT01392469
- Testing
- Imatinib, Sildenafil, Bosentan
- Where
- 11 sites in United States, Australia and 5 more
- Volunteers
- 21 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension, Resistant to Conventional Therapy
Safety and Efficacy Study of Extracorporeal Shockwave Therapy in the Treatment of Patients With Resistant Hypertension
Low intensity shockwaves have been proven in animal and human studies to increase tissue perfusion, promote angiogenesis and tissue regeneration and improve neural function.
- Trial name
- RHT (NCT02042066)
- Testing
- Omnispec model Vascuspec
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Medispec
Hypertension
Device Based Therapy in Hypertension Trial
The purpose of this study is to demonstrate the safety and efficacy of the Rheos Baroreflex Hypertension Therapy System in patients with refractory hypertension.
- Trial name
- DEBuT-HT (NCT00710190)
- Testing
- Rheos Baroreflex Hypertension Therapy System
- Where
- 9 sites in Czechia, Germany and 4 more
- Volunteers
- 46 people
- Sponsor
- CVRx, Inc.